Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.

Start Date21 Apr 2024

Sponsor / Collaborator

Korea University Anam Hospital

[+8]

100 Clinical Results associated with Kyung Hee University Hospital at Gangdong

0 Patents (Medical) associated with Kyung Hee University Hospital at Gangdong

2,672

Literatures (Medical) associated with Kyung Hee University Hospital at Gangdong

01 Jun 2025·European Journal of Surgical Oncology

Intraperitoneal paclitaxel with systemic S-1 plus oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis: A single-arm, multicenter phase II clinical trial

Article

Author: Kim, Jong-Han ; Jang, You-Jin ; Jee, Ye Seob ; Park, Joong-Min ; Lee, Chang Min ; Choi, Sung Il ; Oh, Sang Chul ; Park, Ji Yeon ; Kim, Jong Won ; Kim, Dong-Wook ; Seo, Won Jun

BACKGROUNDPatients with peritoneal metastasis from gastric cancer show poor prognosis with standard systemic chemotherapy. This prospective multicenter phase II clinical trial was performed to evaluate the efficacy and safety of intraperitoneal paclitaxel combined with systemic S-1 plus oxaliplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.PATIENT AND METHODPatients with advanced or recurrent gastric cancer with histologically or radiologically confirmed peritoneal metastases were eligible for the study. The chemotherapy regimen consisted of eight cycles of intraperitoneal paclitaxel 80 mg/m² on days 1 and 8, combined with 80 mg/m² S-1 for days 1-14, and 100 mg/m² oxaliplatin on day 1, repeated every 21 days. The primary endpoint was 6-month progression-free survival. One-year progression-free and overall survival, response rate, and safety were set as the secondary endpoints.RESULTIn total, 28 patients were included in the study, of which 24 were analyzed, with the exception of those lost to follow-up and withdrawal of consent. The 6-months progression-free survival was 82.6 % (95 % CI: 68.5-99.6 %). The one-year progression-free and overall survival rates were 69.6 % (95 % CI: 53.1-91.2 %) and 76.9 % (95 % CI: 61-97 %), respectively. The overall response rate was 41.67 %. The hematologic toxicity profile showed grade 3/4 hematologic toxicities such as leukopenia (20.8 %), neutropenia (41.7 %), and thrombocytopenia (8.3 %). The only non-hematologic adverse event was grade 3 diarrhea. Three (12.5 %) patients experienced intraperitoneal chemoport-related adverse events.CONCLUSIONBidirectional intraperitoneal paclitaxel with systemic S-1 plus oxaliplatin shows promising efficacy and safety in the treatment of peritoneal metastatic gastric cancer.

01 Jun 2025·European Journal of Surgical Oncology

Survival benefit of adjuvant chemotherapy in high-risk patients with colon cancer regardless of microsatellite instability

Article

Author: Park, Soo Yeun ; Jeong, Woon Kyung ; Kim, Min Sung ; Kim, Kyeong Eui ; Park, Youn Young ; Kim, Chang Woo ; Lee, Jong Lyul ; Ha, Gi Won ; Park, Eun Jung ; Yang, Chun-Seok ; Kim, So Hyun ; Kim, Chang Hyun ; Lee, JaeIm ; Son, Gyung Mo ; Lee, Kyung Ha ; Kim, Duck-Woo ; Bae, Sung Uk ; Ji, Woong Bae ; Han, Yoon Dae ; Baek, Seong Kyu

INTRODUCTIONThe predictive utility of high-risk features (HRFs) and microsatellite instability (MSI) status for adjuvant chemotherapy (ACT) in patients with stage II colon cancer remains unclear. We examined the impact of HRFs and MSI in predicting the benefits of adjuvant ACT in patients with stage II colon cancer.MATERIALS AND METHODSWe included 1801 patients with resected stage II colon cancer who underwent ACT (5-fluorouracil [FU] and oxaliplatin) or surgery alone between January 2010 and December 2017. The primary outcomes were overall survival (OS) and disease-free survival (DFS).RESULTSAmong MSI-high patients with HRFs, patients who received 5- FU and oxaliplatin-based ACT had significantly higher OS and DFS than patients who did not, with no significant difference between those who received 5-FU and oxaliplatin as ACT. Among MSI-low/microsatellite stable patients with HRFs, patients who received 5-FU and oxaliplatin as ACT had significantly higher OS and DFS than patients who did not, with no significant differences between those who received 5-FU and oxaliplatin as ACT. Among patients who did not receive ACT, OS and DFS were 95.0 % and 91.2 % for patients without HRFs, respectively, and 84.4 % and 75.0 % for patients with HRFs, respectively. ACT improved the survival rates of patients with HRFs (OS: 84.4 %→95.9 %, DFS: 75.0 %→88.9 %).CONCLUSIONSACT can be recommended for patients having stage II colon cancer with one or more HRF(s) for recurrence, regardless of the MSI status. In patients with HRFs, we observed no significant difference regarding survival between those who received 5-FU and oxaliplatin-based ACT.

01 May 2025·Sleep Medicine

Continuous REM sleep without atonia quantification improves prediction of phenoconversion to α-synucleinopathies in isolated REM sleep behavior disorder

Article

Author: Noh, Tae-Gon ; Shin, Dae-Seop ; Lee, Seolah ; Jung, Ki-Young ; Byun, Jung-Ick ; Lee, Yoonkyung ; Kim, Han-Joon ; Shin, Jung-Hwan ; Kim, Namoh

STUDY OBJECTIVESisolated REM sleep behavior disorder (iRBD), characterized by REM sleep without atonia (RWA), is considered a prodromal stage of α-synucleinopathies. This study aims to evaluate the predictive potential for phenoconversion of cumulative RWA percentage (CRWA%) as a continuous quantification of RWA compared to conventional epoch-based methods.METHODSBaseline video-polysomnograms from 92 iRBD patients were analyzed. Eleven patients converted to α-synucleinopathies during follow-up (iRBD-CV), while the remaining patients did not (iRBD-NC). RWA quantification was performed using a validated in-house algorithm in mentalis (MT) and bilateral flexor digitorum superficialis (FDS) muscles. Receiver operating characteristic curves, Kaplan-Meier survival analysis, and Cox proportional hazards models were used to assess predictive performance.RESULTSThe iRBD-CV group had significantly higher CRWA%, REM atonia index, and any RWA (using SINBAR and AASM methods) compared with the iRBD-NC group (p < 0.035). Among these metrics, CRWA% demonstrated the highest predictive performance, with an area under the curve (AUC) of 0.89 in the combined MT and FDS channels. Survival analysis showed that patients with CRWA% > 32.54 % had significantly reduced disease-free rates (p = 0.004), with 3-year and 5-year rates of 51.4 % and 25.7 %, respectively. Additionally, higher CRWA% was significantly associated with a higher phenoconversion risk (Hazard ratio = 1.063, p = 0.006).CONCLUSIONCRWA% provides a more precise and continuous approach to quantifying RWA, outperforming traditional methods in predicting phenoconversion to α-synucleinopathies in iRBD. These findings underscore the potential of CRWA% as a robust biomarker for early neurodegenerative progression.

100 Deals associated with Kyung Hee University Hospital at Gangdong

100 Translational Medicine associated with Kyung Hee University Hospital at Gangdong

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Jaungo	Dermatitis, Atopic More	Pending
Bosinji	Low Back Pain More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Kyung Hee University Hospital at Gangdong

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 10 May 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing